NCT02135627View on ClinicalTrials.gov

TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
MALIGNANT GASTROINTESTINAL BLEEDING
Interventions
DRUG

TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.

OTHER

Current standard therapy

Trial Locations (1)

H3G 1A4

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

ASGE

UNKNOWN

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02135627 - TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL. | Biotech Hunter | Biotech Hunter